Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Shares Outstanding (Diluted Average) (2016 - 2025)

Palisade Bio has reported Shares Outstanding (Diluted Average) over the past 9 years, most recently at $55.7 million for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 3830.18% to $55.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $55.7 million through Dec 2025, up 3830.18% year-over-year, with the annual reading at $55.7 million for FY2025, 3830.18% up from the prior year.
  • Shares Outstanding (Diluted Average) was $55.7 million for Q4 2025 at Palisade Bio, up from $5.7 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $55.7 million in Q4 2025 and troughed at $287702.0 in Q1 2023.
  • The 5-year median for Shares Outstanding (Diluted Average) is $974197.0 (2022), against an average of $5.4 million.
  • Year-over-year, Shares Outstanding (Diluted Average) tumbled 91.95% in 2022 and then soared 3830.18% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $12.1 million in 2021, then plummeted by 92.73% to $880311.0 in 2022, then plummeted by 48.2% to $456014.0 in 2023, then soared by 210.62% to $1.4 million in 2024, then soared by 3830.18% to $55.7 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Shares Outstanding (Diluted Average) are $55.7 million (Q4 2025), $5.7 million (Q3 2025), and $4.8 million (Q2 2025).